BioSpace News Archive

Conference call and live webcast scheduled for Thursday, March 12th, 2020 at 8:30 am EDT

McKesson Corporation (NYSE:MCK) today announced the final results of its offer to its stockholders to exchange their issued and outstanding shares of McKesson common stock for shares of PF2 SpinCo, Inc. (“SpinCo”) common stock owned by McKesson as part of its split-off of its interest in Change Healthcare LLC (“Change Healthcare”) and its agreement with Change Healthcare Inc. (NASDAQ:CHNG) (“Change”) to merge SpinCo with and into Change.

Hologic (Nasdaq: HOLX) announced today the 1,000th placement of a Panther system, the Company’s market-leading automated molecular instrument, in a United States diagnostics laboratory

Vifor Pharma Group recorded strong financial and operational performance in 2019 by focusing on its three strategic growth drivers while continuing to invest in its pipeline.

AstraZeneca and Merck announced high-level results from the Phase 3 GY004 trial, led by NRG Oncology and sponsored by the U.S. National Cancer Institute, that examined primarily the efficacy and safety of investigational medicine cediranib in combination with LYNPARZA versus platinum-based chemotherapy in patients with platinum-sensitive relapsed ovarian cancer.

Transmission speed of the Covid-19 virus remains difficult to assess, and Castellum is closely following developments.

Bactiguard launches HYDROCYN aqua®, a water-based product that has been proven to have a powerful effect on killing previous variants of coronavirus within 15-30 seconds.

Teva Pharmaceutical Europe BV an affiliate of Teva Pharmaceutical Industries Ltd. announced that the National Institute for Health and Care Excellence has recommended AJOVY in its Final Appraisal Document for the prevention of migraine in adults with chronic migraine.

Pulling no punches, the UCLA Anderson Forecasts for the national, state and global economies take a hard look at the potential impacts of COVID-19.

Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to invent breakthrough protein degrader medicines for patients, announced the closing of a $102 million Series C financing.